Compare Macy's Inc (M) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Macy's Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Macy's Inc trades at $22.67 (market cap $5.95B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and Macy's Inc pays a 3.36% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Macy's Inc for 58 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| M | XBI | |
|---|---|---|
Market Cap | $5.95B | $10.11B |
Volume | 6,030,644 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $26.21 | $169.55 |
52-Week Low | $16.51 | $104.99 |
Typical Hold Time | 58 Days | 38 Days |
Enterprise Value | $9.75B | — |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Macy's (M) trades at $22.79 with strong valuation metrics including a P/E of 8.35 and P/S of 0.27, suggesting potential undervaluation. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.63 exceeding expectations by 70%. Technical indicators show a bullish trend with support at $22 and resistance at $23-24, while the RSI at 28.95 suggests potential oversold conditions. Recent news highlights Macy's 'Bold New Chapter' strategy driving digital transformation and sales growth.
The outlook remains cautiously optimistic with a 3.5% dividend yield providing income support. Analyst consensus targets $24.25 with 32% buy ratings, though execution risks persist amid retail sector challenges. Key catalysts include continued digital transformation success and margin improvement, while risks involve competitive pressures and uneven quarterly performance.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
